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Drug discovery to lessen the burden of chronic renal failure
and end-stage renal disease remains a principle goal of
translational research in nephrology. In this review, we
provide an overview of the current development of small
molecule cyclin-dependent kinase (CDK)/glycogen synthase
kinase-3 (GSK-3) inhibitors as therapeutic agents for
parenchymal renal diseases. The emergence of this drug
family has resulted from the recognition that CDKs and
GSK-3s play critical roles in the progression and regression
of many kidney diseases. CDK/GSK-3 inhibitors suppress
pathogenic proliferation, apoptosis, and inflammation, and
promote regeneration of injured tissue. Preclinical efficacy
has now been demonstrated in mesangial proliferative
glomerulonephritis, crescentic glomerulonephritis, collapsing
glomerulopathy, proliferative lupus nephritis, polycystic
kidney diseases, diabetic nephropathy, and several forms
of acute kidney injury. Novel biomarkers of therapy are
aiding the process of drug development. This review will
highlight these advancements in renal therapeutics.
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Many drugs used in the renal clinic today originated from
their empiric administration to patients with parenchymal
renal diseases, despite limited knowledge of disease patho-
genesis or molecular drug targets. Seminal clinical observa-
tions several decades ago of therapeutic responses from
nitrogen mustard,1 steroids,2 and cyclophosphamide3 in
various nephritic and nephrotic renal lesions laid the early
foundation for the ongoing empiric use of immunomodu-
latory drugs to treat many kidney diseases. Recent ‘top-down’
translational research4 to better understand how these drugs
may confer efficacy, however, continue to uncover unex-
pected mechanisms of drug action,5,6 underscoring recurring
themes in drug discovery: efficacy often results from the
integrative rather than the singular action of drugs, and the
specificity of drug action is contextual and differs depending
on how the molecular targets of drugs promote or resolve any
particular disease.
Here, we discuss the development of small molecule
cyclin-dependent kinase (CDK)/glycogen synthase kinase-3
(GSK-3) inhibitors (CGIs) as therapeutic agents for paren-
chymal renal diseases. In contrast to discoveries through
‘top-down’ translational research, the growing interest in
CGIs has come via the ‘bottom-up’ recognition4 in molecular
nephrology that CDKs and GSK-3s are integrally involved in
the pathogenesis and repair of many forms of renal injury.
Because these paralogous kinases enter into several biologic
processes both within and outside the kidney,7–14 CGIs share
with many other renal therapeutic agents the propensity for
promiscuity in achieving efficacy.15,16 This is also evidenced
by the ongoing development of CGIs for use in many other
diseases, including cancer, diabetes, cardiovascular and
neurodegenerative disorders, several viral and parasitic
infections, systemic inflammatory syndromes, and in regen-
erative medicine.7–14
CGIs AND KINASE SELECTIVITY
The CDK and GSK-3 families of serine/threonine kinases are
closely related phylogenetically,17,18 and studies in chemical
proteomics19,20 uncovered their overlapping sensitivity to
several chemically diverse small molecules.21–25 Twenty CDKs
(CDK-1 through CDK-13 plus seven CDK-like kinases for
which cyclin-binding partners have not been identified) and
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two GSK-3s (GSK-3a and GSK-3b) exist in the mammalian
kinome and share high structural similarity at their ATP-
binding and catalytic domains.17,18,25 Despite the divergent
feature that CDKs but not GSK-3s typically require protein-
binding partners (that is, cyclins) to induce kinase activity,7,8
both families are inhibited by several of the same CGIs.21–25
In most cases, this occurs because these ‘pan-selective’ CGIs
compete with ATP for docking at the ATP-binding pocket
within CDKs and GSK-3s at similar potencies.21–25 These
pan-selective CGIs constitute a diverse repertoire of small
molecules and include analogues of the purines, pyrimidines,
maleimides, flavones, indirubins, along with members of
many other chemical classes.21–25
Modifications around the chemical scaffold of many pan-
selective GCIs can logarithmically increase or decrease
selectivity for specific CDK and GSK-3 family members.21–25
This selectivity is typically demonstrated by in vitro assays
utilizing purified kinases, representative substrates, and
steady-state concentrations of drug.21–25 Whether this
selectivity exists during drug administration in vivo, however,
is less clear. As with all other small molecule drugs, the
pharmacokinetics and pharmacodynamics of each CGI
factors importantly into its target selectivity during treatment
regimens.26 Indeed, in the absence of type I biomarkers to
directly detect and monitor the modulation of potential drug
targets in vivo, the selectivity of CGIs in vivo is largely
extrapolated from in vitro kinase assays, cell culture-based
assays, and surrogate/type II biomarkers of drug activity.15,27
Combined with the fact that CGIs (along with other kinase
inhibitors) have not been screened against all known kinases
or other nucleotide-interacting proteins, delineating the
selectivity of CGIs remains an important focus of research
on this drug family.19,20 Table 1 lists the CGIs that have been
studied in renal diseases to date along with their in vitro
kinase inhibitory profiles.
PATHOGENIC AND REPARATIVE PHENOTYPES TARGETED BY
CGIs
CDKs and GSK-3s are involved in several essential physio-
logic responses,7–14 and their aberrant activities have been
implicated in the pathogenesis of multiple parenchymal renal
diseases. Figure 1 depicts several of the major molecular
pathways controlled by CDKs and GSK-3s, which have been
modulated by GCIs to preserve renal function. Of disease
phenotypes, the ability of GCIs to suppress proliferation,
apoptosis, and inflammation has received the greatest
attention. Because these phenotypes often coexist and
synergize to promote progressive injury to the renal
parenchyma, CGIs harbor the inherent ability to simulta-
neously target multiple aspects of disease pathogenesis.
Table 2 lists the therapeutic responses to CGIs by
various cell types both within and outside the kidney that
have been implicated in the development of parenchymal
renal diseases.
CGIs may also promote remodeling and repair of injured
renal parenchyma (Figure 1). The GSK-3b inhibitor, lithium,
and the CGI, 6-bromoindirubin-30-oxime (BIO), promote
survival of growth factor-deprived renal epithelial cells by
activating the Wnt pathway.57 Wnt signaling is induced in
renal epithelial cells subjected to ATP depletion–repletion,
causing nuclear translocation of b-catenin to activate
lymphocyte enhancer-binding factor/T cell factor (LEF/
TCF)-mediated gene expression.58 In response to ischemia–
reperfusion injury, Wnt-4 expression increases, and, via
b-catenin, upregulates the expression of cyclin D1 to
promote cell-cycle progression.59 Thus, activation of Wnt
signaling in response to renal injury may promote the repair
of injured renal parenchyma, preserving renal function.
Wnt signaling via GSK-3b is also a key regulator of the
pluripotency and function of stem cells,14 a focus of
increasing importance in regenerative medicine of the
kidney.60 Current evidence suggests that bone marrow stem
cells facilitate the recovery of injured renal parenchyma by
differentiating into renal parenchymal cells and/or by acting
in a paracrine manner to facilitate the local intrarenal
regenerative response.61–66 Additionally, renal stem cell niches
reside within the kidney,67,68 from which progenitors may be
recruited locally to facilitate repair of injured parenchyma.60
Thus, CGIs may have therapeutic applications in regenerative
therapies for the kidney.14 Proof of this concept already exists
for some CGIs that have been shown to sustain the
pluripotent state of embryonic stem cells in vitro,69 to
promote hematopoietic stem cell repopulation in vivo,70 and
to promote nephrogenesis ex vivo.56
Table 1 | Kinase inhibitory profiles (IC50 in lM) for CGIs studied in renal diseases
Inhibitora Class CDK-1 CDK-2 CDK-4 CDK-5 CDK-7 CDK-9 GSK-3a/b Refs.
6-Bromo-indirubin-
30-oxime
Indole 0.32 0.3 10 0.08 — — 0.005 Meijer et al.,23
Polychronopoulos et al.28
Flavopiridol Flavone 0.06 0.15 0.4 0.17 0.3 0.006 0.45 Leclerc et al.,22 Chao et al.29
Olomoucine Purine 7 7 4100 3 — — 100 Vesely et al.30
Purvalanol B Purine 0.006 0.006 410 0.006 — — 410 Leclerc et al.,22 Gray et al.31
R-roscovitine Purine 0.45 0.13 14.7 0.16 0.49 0.78 130 Leclerc et al.,22 Raynaud et al.32
SB216763 Maleimide 0.55 — — — — — 0.034 Meijer et al.,11 Coghlan et al.33
SB415286 Maleimide 0.9 — — — — — 0.078 Meijer et al.,11 Coghlan et al.33
TDZD-8 Thiadiazolidinone 410 — — — — — 2 Meijer et al.,11 Martinez et al.34
CDK, cyclin-dependent kinase; CGI, cyclin-dependent kinase/glycogen synthase kinase-3 inhibitor; IC50, half-maximal inhibitory concentration; TDZD-8, thiadiazolidinone-8.
aThe full profile of some CGIs is not known.
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PRECLINICAL EFFICACY IN MANY KIDNEY DISEASES
Mesangial proliferative glomerulonephritis
The first preclinical study providing proof-of-concept that
CGIs may be efficacious in proliferative and immunologic
renal diseases utilized the rat anti-Thy1.1 model of mesangial
proliferative glomerulonephritis.35 Administration of rosco-
vitine to rats either before or 3 days after induction of
mesangial proliferative glomerulonephritis with anti-Thy1.1
antibody markedly decreased mesangial cell proliferation,
mesangial matrix production, and renal insufficiency as
measured by urine (protein/creatinine) and blood urea
nitrogen levels at day 10 after disease onset. This ground-
breaking report contributed to the rationale for clinical trials
of roscovitine in patients with IgA nephropathy.15
Crescentic glomerulonephritis and collapsing
glomerulopathy
The diagnoses of crescentic glomerulonephritis and collap-
sing glomerulopathy, nephritic and nephrotic manifestations
of glomerular epithelial cell proliferation, respectively,
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Figure 1 | Molecular pathways of proliferation, apoptosis, inflammation, and tissue morphogenesis that have been modulated by
CGIs to preserve renal function. The kinase targets of CGIs and their substrates are shown in green and red, respectively. (a) CDKs
promote engagement (G0 to G1) and progression (G1 to M) of the cell cycle. Among several substrates, phosphorylation (P) of the
retinoblastoma protein (Rb) by CDKs allows for proliferating cells to transition into the S phase of the cell cycle. (b) GSK-3s can phosphorylate
both MCL-1, increasing free BIM, and BAX. Both events promote permeation of mitochondria, thereby releasing cytochrome c and
activating proapoptotic cascades in cells. (c) CDKs can also influence proliferation, apoptosis, and inflammation through direct control of
gene expression. One example is the liberation of E2F transcription factors and expression of E2F-dependent pro- or antiapoptotic genes
following phosphorylation of Rb by CDK-2. Another example is the phosphorylation of RNA polymerase (pol) II by CDK-7 and CDK-9,
thereby supporting expression of short-lived mRNAs required for cell-cycle progression. (d) GSK-3s promote proinflammatory NF-kB-mediated
gene expression. Multiple steps in the activation of NF-kB transcription factors have been implicated, including phosphorylation of IkB and
the p65 subunit of NF-kB, and release of the NF-kB transcription cofactor, CBP, from sequestration by CREB following phosphorylation of
CREB. (e) GSK-3s are central to tissue morphogenesis and repair in the kidney, as exemplified by the role of GSK-3s in determining the fate
of b-catenin in Wnt signaling. IkB, inhibitor kB; MCL-1, myeloid cell leukemia-1. CREB, cAMP response element-binding protein;
CBP, CREB-binding protein.
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portend rapid losses in renal function. Administration of
roscovitine to rats with the nephrotoxic form of crescentic
glomerulonephritis or to mice with the anti-total glomerular
protein form of crescentic glomerulonephritis/collapsing
glomerulopathy ameliorated crescent formation, glomerular
matrix deposition, and the accompanying renal insuffi-
ciency.16,37 Treatment of Tg26 mice, an established model
of HIV-induced collapsing glomerulopathy, with flavopiridol
or roscovitine prevented and reversed existing renal dis-
ease.38–41 Because CGIs could also suppress HIV gene
expression, these studies in Tg26 mice demonstrated for
the first time that CGIs may simultaneously target both the
etiologic and phenotypic manifestations of renal disease.38–41
The safety of CGIs in states of glomerular epithelial cell injury
was also supported by studies in the passive Heymann
nephritis model of membranous nephropathy.71
Proliferative lupus nephritis
The ability of CGIs to target both intrarenal and extrarenal
contributions to parenchymal injury was recently demons-
trated in the (NZBNZW) mouse model of proliferative
lupus nephritis.36,49 Administration of roscovitine to (NZB
NZW) mice with early or established proliferative lupus
nephritis significantly reduced glomerular hypercellularity,
tubulointerstitial damage, leukocyte inflammation, immu-
noglobulin and complement deposition, and proteinuria.
When roscovitine was combined with low-dose steroids, the
survival of (NZBNZW) mice was markedly enhanced
when compared to either agent alone. These studies
demonstrated that direct suppression by roscovitine of the
extrarenal, autoimmune T- and B-lymphocyte responses
contributed to the amelioration of proliferative lupus
nephritis.
Polycystic kidney diseases
Polycystic kidney diseases (PKDs), the leading genetic
disorders for end-stage renal disease, are caused by dysfunc-
tional cilia that trigger abnormal proliferation, apoptosis, and
dedifferentiation of tubular epithelium.72 Treatment of jck
and cpk mice, models of slowly and rapidly progressive forms
of PKDs, respectively, with roscovitine induced long-lasting
arrest of renal cystogenesis along all segments of the
nephron.42 This occurred even with interrupted dosing
regimens, suggesting sustained correction of the abnormal
renal epithelial phenotype with drug treatment. Efficacy
correlated with roscovitine’s ability to induce cell-cycle arrest,
suppress apoptosis, and attenuate the heightened activity of
RNA polymerase II in diseased kidneys.
Table 2 | Therapeutic responses by various cell types implicated in the progression and regression of renal diseases
Therapeutic response Proposed specificity of action of CGIs Refs.
Antiproliferative
Mesangial cell Cell-cycle arrest by inhibiting cell cycle and transcriptional
CDKs
Pippin et al.,35 Zoja et al.36
Podocyte Cell-cycle arrest by inhibiting cell cycle and transcriptional
CDKs
Griffin et al.,37 Nelson et al.,38 Nelson
et al.,39 Nelson et al.,40 Gherardi et al.41
Renal tubular epithelium Cell-cycle arrest by inhibiting cell cycle and transcriptional
CDKs
Bukanov et al.42
Antiapoptotic
Mesangial cell Lack of caspase activation by inhibiting CDK-2; stabilization
of b-catenin by inhibiting GSK-3b
Lin et al.,43 Hiromura et al.44
Renal tubular epithelium Lack of caspase activation by inhibiting CDK-2 or CDK-5; lack
of E2F1 activation by inhibiting CDK-2
Bukanov et al.,42 Price et al.,45
Price et al.,46 Price et al.,47 Yu et al.48
Anti-inflammatory
Renal tubular epithelium Suppression of NF-kB-mediated expression of cytokines and
chemokines by inhibiting GSK-3b; suppression of expression
of pattern recognition receptors
Dugo et al.,13 Benigni et al.,49
Gong et al.50
Renal endothelium Suppression of NF-kB-mediated expression of adhesion
molecules by inhibiting GSK-3b
Gong et al.,51 Gong et al.52
T lymphocytes Suppression of proliferation and cytokine secretion by
inhibiting CDKs
Zoja et al.36
B lymphocytes Suppression of proliferation and immunoglobulin
production by inhibiting CDKs
Zoja et al.36
Macrophages and
myeloid dendritic cells
Suppression of differentiation and proinflammatory
activation by inhibiting GSK-3b
Martin et al.,53 Rodionova et al.54
Neutrophils Debulking via enhanced apoptosis by inhibiting CDKs Rossi et al.55
Reparative
Renal tubular epithelium Cell-cycle engagement via activation of Wnt signaling by
inhibiting GSK-3b
Kuure et al.56
Renal stem cell niches Maintenance of pluripotency and recruitment by inhibiting
GSK-3b
Romagnani et al.,14 Sinha et al.57
CDK, cyclin-dependent kinase; CGI, cyclin-dependent kinase/glycogen synthase kinase-3 inhibitor; GSK-3b, glycogen synthase kinase-3b; NF-kB, nuclear factor-kB.
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Diabetic nephropathy
High-glucose-induced apoptosis of mesangial cells contri-
butes to the development of glomerulosclerosis in diabetic
nephropathy, a sequelae of signaling by GSK-3b in mesangial
cells.43 Administration of BIO to rats with streptozotocin-
induced diabetic nephropathy suppressed mesangial cell
apoptosis, as measured by TUNEL (TdT-mediated dNTP
nick end labeling) staining in situ, and ameliorated
proteinuria.43 Since GCIs are also being developed to
potentiate insulin signaling as a strategy to lower glucose
levels in type II diabetes,12 their use in diabetic nephropathy
represents another kidney disease in which GCIs may target
both the etiologic and phenotypic manifestations of renal
injury.
Acute kidney injury
In acute kidney injury (AKI), damaged renal epithelial cells
either recover to promote repair or undergo cell death. The
endogenous CDK-2 inhibitor, p21, has been suggested from
in vitro and in vivo models of ischemic and cisplatin-induced
AKI to serve as the cell-cycle checkpoint governing this
response.73,45–48 Induction of p21 during AKI allows injured
cells to undergo repair prior to cell replication, whereas in the
absence of p21, injured cells prematurely engage E2F1-
dependent cell-cycle and apoptotic pathways, promoting
further injury.73,45–48 Indeed, roscovitine and purvalanol were
found to protect from cisplatin-induced AKI with preserva-
tion of kidney morphology and function.46,47
CGIs also attenuate AKI in the setting of systemic
inflammatory response syndromes.13 A central pathogenic
feature of systemic inflammatory response syndromes is the
robust and systemic release of multiple NF-kB-dependent
proinflammatory mediators that have detrimental effects on
several organs, including the kidney.13 Because of the direct
control of NF-kB activation by GSK-3b, TDZD-8, SB216763,
and SB415286 were tested in several preclinical models of
systemic inflammatory response syndromes and found to
markedly suppress proinflammatory cytokine release and
ameliorate AKI.13 It is unknown but reasonable to consider
that these CGIs also modulated NF-kB-independent path-
ways within the renal parenchyma that also contributed to
their efficacy in these studies (Figure 1).
THE CHALLENGE OF CLINICAL DEVELOPMENT
The high rates of attrition of promising therapeutic agents
such as CGIs during preclinical-to-clinical development is a
well-recognized challenge of new drug discovery.15,74,75 While
the reasons for this are multifactorial, leading among them
are problems with absorption, distribution, metabolism,
excretion, and toxicity (ADMET).26,76 This exists not only for
new drug entities but also in the off-label use of Food and
Drug Administration (FDA)-approved drugs for renal
diseases where ADMET is poorly understood.77 For example,
clinical trials of the cancer drug, Gleevac, in IgA nephropathy
were halted over concerns of potential toxicities with
its prolonged use in this typically indolent disease.15
Notwithstanding, attrition remains a force for exploring
alternative therapeutic activities of established drugs in
parenchymal renal diseases, as exemplified, among many
others, by the retinoids,78 3-hydroxy-3-methyl-glutaryl-CoA
reductase inhibitors,79 and peroxisome proliferator-activated
receptor-g agonists.80
Another common reason for attrition is that preclinical
efficacy may not predict clinical efficacy.81 This is particularly
true when preclinical studies do not mimic the clinical reality
of treating existing renal disease, often the case with patients
in nephrology. Most of the preclinical studies listed above
tested treatment, not just prevention, by CGIs. (One notable
exception is prophylaxis for AKI, a relatively minor clinical
need compared to the burden from established AKI.) Yet, no
animal model of renal disease can exactly recapitulate the
varieties of patients. Moreover, due to a paucity of type I
biomarkers, most preclinical studies utilize type II bio-
markers to infer the specificity of drug action, which may
ultimately differ in clinical settings.15,27 Indeed, many
existing type II biomarkers such as creatinine, while
uninformative of drug mechanism, may also not be sensitive
enough to detect early responses to CGIs to help in selecting
lead drug candidates (discussed next).
BIOMARKERS OF THERAPY
The translation of CGIs into renal therapeutic agents could
be accelerated by the discovery and implementation of novel
biomarkers of therapy.15,27,82,83 Many parenchymal renal
diseases that may benefit from CGIs are not only difficult to
diagnose early but also progress with significant variability.
As a result, the task of delineating the specificity and efficacy
of CGIs with existing biomarkers may become quite complex
and cumbersome. For example, the Consortium for Radio-
logic Imaging Studies of PKD cohort recently determined
that quantitative magnetic resonance imaging could predict
the clinical progression and, presumably, regression of PKD
in patients with kidney volumes greater than 1500 ml.84
However, this sophisticated imaging modality as a biomarker
to determine responses to therapy is not widely available and
may not capture the efficacy of CGIs in PKD patients with
smaller kidneys.85
Studies of the urine proteome in PKD exemplifies how
novel biomarkers may facilitate the development of CGIs.82,83
Application of SELDI-TOF (surface-enhanced laser desorp-
tion/ionization time-of-flight) mass spectrometry86 to frac-
tionate proteins in the urine of wild-type mice and jck mice
with PKD creates a banding pattern by gel view that readily
discriminates between normal and diseased kidneys (Figure 2;
N Bukanov, personal communication). During administra-
tion of roscovitine to ameliorate PKD,42 the SELDI-TOF
banding pattern of the urine proteins from jck mice returns
to one that is similar to that of wild-type mice, indicating
establishment of a more normal phenotype and physiologic
loss of proteins from diseased tubular epithelium with
therapy. Thus, assaying for differentially excreted urine
proteins in experimental animals and humans during therapy
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could provide a valuable and rapid tool to screen and validate
GCIs, and ultimately guide drug development and ther-
apy.82,83 Although these types of biomarkers of therapy
clearly require further study, they may be extremely useful in
the development of CGIs as renal therapeutic agents.
CONCLUDING REMARKS
GCIs are promising new therapeutic agents for many
parenchymal renal diseases. Cumulative evidence suggests
that CGIs confer efficacy through multiple mechanisms that
may include the targeting of intrarenal and extrarenal
components of disease pathogenesis and repair, and the
etiology for renal injury. Depending on the context in which
CDKs and GSK-3s enter into the progression or regression of
specific parenchymal renal diseases, the selectivity of CGIs
and the timing of drug treatment for optimal therapeutic
benefit are important areas of future research on this drug
family. This inquiry will be aided by the application of novel
biomarkers of drug mechanism and therapy that should
accelerate the drug discovery process and the use of CGIs in
the renal clinic.
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